<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT922-7008</title>
	</head>
	<body>
		<main>
			<p>920520 FT  20 MAY 92 / International Company News: Astra surges on strong Losec sales ASTRA, the Swedish pharma-ceutical company, boosted pre-tax profits by 40 per cent to SKr1.063bn (Dollars 185.2m) in the first quarter of 1992 from SKr757m in the corresponding period of 1991. The company again forecast that profits for the full year would rise between 20 and 25 per cent to over SKr4bn. Sales for the quarter climbed 35 per cent to SKr3.7bn from SKr2.7bn, while profit per share rose by 45 per cent to SKr5.55 from Skr3.85. Sales of Losec, the company's highly successful stomach ulcer drug and the main competitor of Glaxo's Zantac, increased by 72 per cent in the first quarter to SKr991m from SKr577m, with the biggest markets being in Germany, France and Britain. Total sales of Losec (including those made through licence-holders in the US, Italy and Spain) reached SKr1.550bn from SKr880m. Astra's asthma agent Pulmicort enjoyed a 57 per cent sales increase in the first quarter to SKr414m against SKr264.</p>
		</main>
</body></html>
            